Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CAR T in patients with large B-cell lymphoma not fit for autologous transplant.
Kuhnl A, Kirkwood AA, Roddie C, Menne T, Tholouli E, Bloor A, Besley C, Chaganti S, Osborne W, Norman J, Gibb A, Sharplin K, Cuadrado M, Correia de Farias M, Cheok K, Neill L, Latif AL, González Arias C, Uttenthal B, Jones C, Johnson R, McMillan A, Sanderson R, Townsend W. Kuhnl A, et al. Among authors: neill l. Br J Haematol. 2023 Jul;202(1):65-73. doi: 10.1111/bjh.18810. Epub 2023 Apr 20. Br J Haematol. 2023. PMID: 37082780
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma.
Roddie C, Neill L, Osborne W, Iyengar S, Tholouli E, Irvine D, Chaganti S, Besley C, Bloor A, Jones C, Uttenthal B, Johnson R, Sanderson R, Cheok K, Marzolini M, Townsend W, O'Reilly M, Kirkwood AA, Kuhnl A. Roddie C, et al. Among authors: neill l. Blood Adv. 2023 Jun 27;7(12):2872-2883. doi: 10.1182/bloodadvances.2022009019. Blood Adv. 2023. PMID: 36724512 Free PMC article.
High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma.
O'Reilly MA, Neill L, Collin SM, Stone N, Springell D, Mensah J, Cheok KPL, Jalowiec K, Benjamin R, Kuhnl A, Roddie C, Sanderson R. O'Reilly MA, et al. Among authors: neill l. Hemasphere. 2024 Jan 26;8(1):e29. doi: 10.1002/hem3.29. eCollection 2024 Jan. Hemasphere. 2024. PMID: 38434533 Free PMC article.
Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.
Oporto Espuelas M, Burridge S, Kirkwood AA, Bonney D, Watts K, Shenton G, Jalowiec KA, O'Reilly MA, Roddie C, Castleton A, Clesham K, Nicholson E, Alajangi R, Prabhu S, George L, Uttenthal B, Gabelli M, Neill L, Besley C, Chaganti S, Wynn RF, Bartram J, Chiesa R, Lucchini G, Pavasovic V, Rao A, Rao K, Silva J, Samarasinghe S, Vora A, Clark P, Cummins M, Marks DI, Amrolia P, Hough R, Ghorashian S. Oporto Espuelas M, et al. Among authors: neill l. Blood Cancer J. 2024 Apr 15;14(1):66. doi: 10.1038/s41408-024-01038-2. Blood Cancer J. 2024. PMID: 38622139 Free PMC article.
Recommendations for early referral of individuals with suspected polymyalgia rheumatica: an initiative from the international giant cell arteritis and polymyalgia rheumatica study group.
Keller KK, Mukhtyar CB, Nielsen AW, Hemmig AK, Mackie SL, Sattui SE, Hauge EM, Dua A, Helliwell T, Neill L, Blockmans D, Devauchelle-Pensec V, Hayes E, Venneboer AJ, Monti S, Ponte C, De Miguel E, Matza M, Warrington KJ, Byram K, Yaseen K, Peoples C, Putman M, Lally L, Finikiotis M, Appenzeller S, Caramori U, Toro-Gutiérrez CE, Backhouse E, Oviedo MCG, Pimentel-Quiroz VR, Keen HI, Owen CE, Daikeler T, de Thurah A, Schmidt WA, Brouwer E, Dejaco C. Keller KK, et al. Among authors: neill l. Ann Rheum Dis. 2024 Oct 21;83(11):1436-1442. doi: 10.1136/ard-2023-225134. Ann Rheum Dis. 2024. PMID: 38050004
59 results